Download - Lymphoma s

Transcript
Page 1: Lymphoma s

Lymphomas

S. Sami Kartı, MD, Prof.

Page 2: Lymphoma s

Conceptualizing lymphoma

neoplasms of lymphoid origin, typically causing lymphadenopathy

Page 3: Lymphoma s

ALLALL MM MM CLLCLL LymphomasLymphomas

Hematopoieticstem cell

Neutrophils

Eosinophils

Basophils

Monocytes

Platelets

Red cells

Myeloidprogenitor

Myeloproliferative disordersMyeloproliferative disordersAMLAML

Lymphoidprogenitor T-lymphocytes

Plasmacells

B-lymphocytes

nanaïïveve

Page 4: Lymphoma s

B-cell development

stemcell

lymphoidprogenitor

progenitor-B

pre-B

immatureB-cell

memoryB-cell

plasma cellplasma cell

DLBCL,FL, HL

ALL

CLL

MM

germinalgerminalcentercenterB-cellB-cell

maturenaiveB-cell

Page 5: Lymphoma s

Clinically useful classification

Diseases that have distinct• clinical features• natural history• prognosis• treatment

Biologically rational classification

Diseases that have distinct• morphology• immunophenotype• genetic features• clinical features

Classification

Page 6: Lymphoma s

Lymphoma classification (2001 WHO)

B-cell neoplasms precursor mature

T-cell & NK-cell neoplasms precursor mature

Hodgkin lymphoma

Non-HodgkinLymphomas

Page 7: Lymphoma s

A practical way to think of lymphoma

Category Survival of untreated patients

Curability To treat or not to treat

Non-Hodgkin lymphoma

Indolent Years Generally not curable

Generally defer Rx if asymptomatic

Aggressive Months Curable in some

Treat

Very aggressive

Weeks Curable in some

Treat

Hodgkin lymphoma

All types Variable – months to years

Curable in most

Treat

Page 8: Lymphoma s

Mechanisms of lymphomagenesis

Genetic alterations Infection Antigen stimulation Immunosuppression

Page 9: Lymphoma s

Epidemiology of lymphomas

5th most frequently diagnosed cancer in both sexes

males > females incidence

NHL increasing Hodgkin lymphoma stable

Page 10: Lymphoma s

Risk factors for NHL

immunosuppression or immunodeficiency

connective tissue disease family history of lymphoma infectious agents ionizing radiation

Page 11: Lymphoma s

Clinical manifestations Variable

severity: asymptomatic to extremely ill time course: evolution over weeks, months, or

years

Systemic manifestations fever, night sweats, weight loss, anorexia, pruritis

Local manifestations lymphadenopathy, splenomegaly most common any tissue potentially can be infiltrated

Page 12: Lymphoma s

Other complications of lymphoma

bone marrow failure (infiltration) CNS infiltration immune hemolysis or

thrombocytopenia compression of structures (eg spinal

cord, ureters) pleural/pericardial effusions, ascites

Page 13: Lymphoma s

Diagnosis requires an adequate biopsy

Diagnosis should be biopsy-proven before treatment is initiated

Need enough tissue to assess cells and architecture open bx vs core needle bx vs FNA

Page 14: Lymphoma s

Stage I Stage II Stage III Stage IV

Staging of lymphoma

A: absence of B symptomsB: fever, night sweats, weight loss

Page 15: Lymphoma s

Three common lymphomas

Diffuse large B-cell lymphoma Follicular lymphoma Hodgkin lymphoma

Page 16: Lymphoma s

Relative frequencies of different lymphomas

Hodgkinlymphoma

NHL

Diffuse large B-cell

Follicular

Other NHL

Non-Hodgkin Lymphomas

~85% of NHL are B-lineage

Page 17: Lymphoma s

Follicular lymphoma most common type of “indolent”

lymphoma usually widespread at presentation often asymptomatic not curable (some exceptions) associated with BCL-2 gene

rearrangement [t(14;18)] cell of origin: germinal center B-cell

Page 18: Lymphoma s

defer treatment if asymptomatic (“watch-and-wait”)

several chemotherapy options if symptomatic

median survival: years despite “indolent” label, morbidity

and mortality can be considerable transformation to aggressive

lymphoma can occur

Page 19: Lymphoma s

Diffuse large B-cell lymphoma

Page 20: Lymphoma s

Introduction

most common type of “aggressive” lymphoma

extranodal involvement is common cell of origin: germinal center B-cell

Page 21: Lymphoma s

Clinical presentation

Usually presents with one or more rapidly growing tumor masses involving nodal or extranodal sites

Not tender Usually not interfere organ function

except by compression

Page 22: Lymphoma s

Treatment

Chemotherapy Radiotherapy Chemotherapy + radiotherapy Autologous or allogeneic stem cell

transplantation in relaps or refractory cases

Page 23: Lymphoma s

Hodgkin lymphoma

Thomas Hodgkin(1798-1866)

Page 24: Lymphoma s

Classical Hodgkin Lymphoma

Page 25: Lymphoma s

Hodgkin lymphoma

cell of origin: germinal centre B-cell Reed-Sternberg cells (or RS variants)

in the affected tissues most cells in affected lymph node are

polyclonal reactive lymphoid cells, not neoplastic cells

Page 26: Lymphoma s

Reed-Sternberg cell

Page 27: Lymphoma s

RS cell and variants

popcorn celllacunar cellclassic RS cell

Page 28: Lymphoma s

A possible model of pathogenesis

germinalcentreB cell

transformingevent(s)

loss of apoptosis

RS cellinflammatory

response

EBV?

cytokines

Page 29: Lymphoma s

Histologic subtypes

Classical Hodgkin lymphoma nodular sclerosis (most common subtype) mixed cellularity lymphocyte-rich lymphocyte depleted

Page 30: Lymphoma s

Epidemiology

less frequent than non-Hodgkin lymphoma

overall M>F peak incidence in 3rd decade

Page 31: Lymphoma s

Associated (etiological?) factors

EBV infection smaller family size higher socio-economic status caucasian > non-caucasian possible genetic predisposition other: HIV? occupation? herbicides?

Page 32: Lymphoma s

Clinical manifestations

lymphadenopathy extranodal sites relatively uncommon

except in advanced disease “B” symptoms

Page 33: Lymphoma s

Treatment and Prognosis

Stage Treatment Overall 5 year

survival

I,II ABVD x 2-4 & radiation

80-90%

III,IV ABVD x 6-8 70-80%

Page 34: Lymphoma s

Long term complications of treatment

infertility MOPP > ABVD; males > females sperm banking should be discussed premature menopause

secondary malignancy skin, AML, lung, MDS, NHL, thyroid,

breast... cardiac disease


Top Related